Health · Pharma & Biotech · 1 hr ago
Retatrutide improves sleep apnea in trials involving adults with obesity
Two randomized trials found retatrutide improved obstructive sleep apnea in adults with obesity or overweight.
The drug is an experimental treatment developed by Eli Lilly.
Obstructive sleep apnea causes repeated pauses in breathing during sleep.
The trials found improvement with or without type 2 diabetes, so the result was not limited to people with that condition.
The findings suggest retatrutide may have a role beyond obesity treatment.
Lilly expects to launch the drug for obesity next year, but no timing for a sleep apnea use is given.
Retatrutide improved obstructive sleep apnea in adults with obesity or overweight, according to two parallel randomized clinical trials.
The reported benefit was seen regardless of whether participants had type 2 diabetes.
Retatrutide is a novel triple agonist being developed by Eli Lilly.
Lilly is also lining up retatrutide for possible use in sleep apnea.
The available reports do not provide trial results beyond the stated mean reduction being reported.
- Who
- Adults with obesity or overweight took part in the trials; Eli Lilly is developing retatrutide.
- What
- Two randomized clinical trials found that retatrutide improved obstructive sleep apnea.
- When
- The reports were published on October 21, 2026.
- Where
- Not stated.
- Why
- The trials assessed retatrutide as a treatment for obstructive sleep apnea.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Drug
- Retatrutide
- Developer
- Eli Lilly
- Condition
- Obstructive sleep apnea
- Trial design
- Two parallel randomized clinical trials
- Participants
- Adults with obesity or overweight
- Reported effect
- Improved sleep apnea regardless of type 2 diabetes